ACADIA Pharmaceuticals Inc. (0A4W.L)

20.91 -0.68 (-3.13%) At close: 07:08PM GMT

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
https://acadia.com

Sector(s): 
Industry: 
Full-time employees: 580

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen R. Davis J.D.	President, CEO & Director	1.46M	N/A	1961
Mr. Mark C. Schneyer	Executive VP & CFO	701.03k	N/A	1974
Mr. Brendan P. Teehan	Executive VP, COO & Head of Commercial	724.31k	N/A	1969
Mr. Austin D. Kim	Executive VP, General Counsel & Secretary	722.15k	N/A	1964
Mr. James K. Kihara	VP, Chief Accounting Officer & Corporate Controller	N/A	N/A	1981
Mr. Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Julie Fisher	Senior Vice President of Marketing & Commercial Strategy	N/A	N/A	N/A
Ms. Holly Valdiviez	Senior VP & Head of Sales	N/A	N/A	N/A
Mr. Rob Ackles	Senior VP & Chief People Officer	N/A	N/A	N/A
Mr. Bob Mischler	Senior Vice President of New Product Planning & Strategy	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

Corporate governance

ACADIA Pharmaceuticals Inc.’s ISS governance QualityScore as of 1 December 2023 is 9. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.